The warning reflects growing concern over a surge in opioid products marketed to US consumers containing concentrated levels of 7-hydroxymitragynine (7-OH).

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

After state lawmakers outlawed the fluoridation of communities' waters, a Utah dentist is testifying to the FDA to encourage ...

UofL Health – Brown Cancer Center recently became the first facility in the United States of America to offer its patients access to an FDA approved assay for solid tumor testing. The test, known as ...

Anthem Biosciences Ltd, a CRDMO founded in 2006, offers end-to-end drug discovery-to-manufacturing services and specialises ...